alexa Raltitrexed based Transcatheter Arterial Chemoembolizat
ISSN: 2167-7700

Chemotherapy: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Raltitrexed based Transcatheter Arterial Chemoembolization (TACE) for Unresectable Hepatocellular Carcinoma: A Single-center Randomized Controlled Study

Yu Wang*, Wei Cui*,Jia Wen, Wenzhe Fan, Yingqiang Zhang, Wang Yao, Kunbo Huang and Jiaping Li*

Department of Interventional Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, PR China

*Corresponding Authors:
Jiaping Li
Department of Interventional Oncology, the First Affiliated Hospital
Sun Yat-sen University, Guangzhou, 510080, PR China
Tel: +86-20-13352890908
E-mail: [email protected]

 
Yu Wang
Department of Interventional Oncology, the First Affiliated Hospital
Sun Yat-sen University
Guangzhou, 510080, PR China

 
Wei Cui
Department of Interventional Oncology
the First Affiliated Hospital, Sun Yat-sen University
Guangzhou, 510080, PR China

Received date: January 07, 2016; Accepted date: February 15, 2016; Published date: February 20, 2016

Citation: Wang Y, Cui W, Wen J, Fan W, Zhang Y, et al. (2016) Raltitrexed based Transcatheter Arterial Chemoembolization (TACE) for Unresectable Hepatocellular Carcinoma: A Single-center Randomized Controlled Study. Chemo Open Access 5:192. doi: 10.4172/2167-7700.1000192

Copyright: © 2016 Jia ping Li, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, andreproduction in any medium, provided the original author and source are credited.

 

Abstract

Background: We aimed to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE), a combination of raltitrexed, oxaliplatin, and epirubicin, for unresectable hepatocellular carcinoma (HCC). Methods: We enrolled 163 patients in this single-center, randomized, controlled trial comparing TACE with epirubicin and oxaliplatin (control group; 83 patients) to TACE with raltitrexed, epirubicin, and oxaliplatin (raltitrexed group; 80 patients).The primary endpoint was overall survival(OS);secondary endpoints included progression-free survival(PFS),tumor response and adverse events. Results: The median progression-free survival (mPFS) and overall survival (mOS) were similar (mPFS: 4.3 vs. 4.6 months, P = 0.201; mOS: 9.6 vs. 9.8 months, P = 0.698, respectively). The disease control rates for the control and raltitrexed groups were 57.8% and 63.8%, respectively, and did not reach statistical significance (P = 0.439). Adverse events were also similar in both the groups (P > 0.05). Conclusion: Although the study did not meet its primary endpoint, the treatment induced a high response rate and promising PFS and OS rates in patients, suggests that the use of raltitrexed as an alternative for TACE may confer some benefit to patients with unresectable HCC.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords